ICICI Bank

Refer to important disclosures at the end of this report

Super-normal performance is the 'New Normal'

- ICICI Bank yet again reported beat on profitability at Rs83.1bn (vs. est. of Rs 80.7bn), led by strong growth, superior margin delivery, and contained opex. Unlike other banks, ICICI continues to build contingent buffer (Rs15bn in 3Q, taking it to Rs115bn/1.1% of loans) to smoothen its profitability trajectory and help absorb any futuristic asset-quality hiccups.
- Credit growth moderated a bit as the overseas book declined but remained healthy at 20% yoy/4% qoq. However, deposit growth lagged at 10% yoy, leading to higher LDR. This coupled with asset re-pricing and favorable loan composition boosted margins to an all-time high of 4.65%, up 34 bps qoq /69bps yoy. We believe margins have peaked and should ease a bit as funding cost catches up.
- We believe ICICI is best placed among large PVBs to deliver growth and absorb any macro/asset-quality shock, given healthy provisions/capital buffers. Thus, we expect the bank to deliver the best-ever RoA/RoE of 2.1-2.2%/17-18% over FY23-25E because of strong margins and lower LLP.
- ICICI remains our top pick in the banking space, given its superior financial performance, top-management stability/credibility, and strong capital/provision buffers. We retain our BUY rating with a revised TP of Rs1,250/share, valuing the bank now at 2.9x Dec-24E and subsidiary value at Rs220/share.
- Superior margin delivery, but needs to ramp-up deposit growth: ICICI reported some moderation in credit growth due to deceleration in the overseas corporate credit book, but it still reported healthy 20% yoy/4% qoq growth. Retail growth remained healthy at 23% yoy/5% qoq despite strong base, while SME engine continued to fire at a strong pace. However, deposit growth lagged at 10% yoy/3% qoq with CASA ratio too moderating a bit to 45%, leading to a 10bps qoq rise in CoF. However, better loan yields and favorable loan composition led to the highest-ever NIMs for the bank at 4.7%, up 34bps qoq. We believe margins have peaked and should ease a bit as funding cost catches up, but would still remain well past 4.2-4.3% in the near-medium term.
- Bank continues to build counter-cyclical buffer to absorb any future asset-quality shock: Gross slippages were higher at Rs57bn/2.8% of loans due to higher retail/corporate slippages as well from the KCC book. However, recovery/upgrades were equally strong, leading to a 12bps qoq reduction in the GNPA ratio to 3.1%. The restructured pool declined to Rs50bn/0.5% (vs. 0.7% in Q2), for which the bank carries provision cover of 31%. The bank continues to strengthen its balance sheet and make it shock-proof, as it made additional contingency provision of Rs15bn in Q3; now the contingency buffer stands at a high of Rs115bn/1.1% of loans. The FB/NFB exposure rated below BB declined to Rs55.8bn/0.6% of loans in Q3, from Rs76.4bn/0.8% of loans in Q2.
- ICICI remains our top pick in the banking space: ICICI remains our top pick in the banking space, given its superior financial performance (best-ever RoA/RoE of 2.1-2.2%/17-18% over FY23-25E), top-management stability/credibility, and strong capital/provision buffers. We retain BUY with a revised TP of Rs1,250/share, valuing the bank now at 2.9x Dec-24E and subsidiary value at Rs220/share. Key risks: Slow macro/consumption hampering the bank's growth and asset quality.

Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Net income	579,578	659,836	810,698	935,878	1,103,449
Net profit	161,926	233,395	315,402	372,097	435,408
EPS (Rs)	24.2	33.7	45.3	53.3	62.4
ABV (Rs)	206.7	234.7	271.4	315.9	368.1
RoA (%)	1.4	1.8	2.1	2.2	2.1
RoE (%)	12.6	15.0	17.5	17.7	17.8
PE (x)	26.9	19.3	14.4	12.2	10.4
P/ABV	3.4	2.9	2.5	2.1	1.8
Source: Company, Emi	سلمم وأصفحه فالمكام والمح	ay@whitemarq u	aesolutions.com	use and down	nloaded at

Emkay[©]

СМР	Target Price
Rs 871 as of (January 21, 2023)	Rs 1,250 (▲) 12 months
Rating	Upside
BUY (∎)	43.6 %

Change in Estimates

•				
EPS Chg FY2	23E/F	Y24E (9	%)	3.8/1.5
Target Price	chang	e (%)		2.0
Target Period	l (Mor	nths)		12
Previous Rec	0			BUY
Emkay vs Co	onsen	sus		
	EPS E	Estimat	es	
		F	Y23E	FY24E
Emkay			45.3	53.3
Consensus			43.9	50.5
Mean Conser	ารus T	TP (12N	I)	Rs 1,100
Stock Details	5			
Bloomberg C	ode		IC	ICIBC IN
Face Value (I	₹s)			2
Shares outsta	anding	g (mn)		6,978
52 Week H/L				958 / 642
M Cap (Rs br	1/USD	bn)	6,07	6 / 74.89
Daily Avg Vol				1,687,510
Daily Avg Tu	nover	· (US\$ r	nn)	130.6
Shareholdin	g Patt	tern De	c '22	
Promoters				-%
FIIs				56.0%
DIIs				36.1%
Public and Of	hers			7.9%
Price Perform	nance	e		
(%)	1 M	3M	6M	12M
Absolute	(4)	(2)	11	7
Rel. to Nifty	(2)	(5)	2	6
Relative price	e cha	ırt		
975 _ Rs				% 20
910 -			hinter	12
845 -		NAME OF	VV Y	4
780 -	La Man	م کر		4
715	ŃΛ.	ľ		12
	γV	V		
650 / / / Jan-22 Mar-221		Jul-22 Sej		
ICICIBC	IN Equity (I	LHS) —	Re	to Nifty (RHS)
Source: Bloom	berg			
This report is sol following person production of the	(s) are i	responsit	ole for th	
Heet Khimaw	vat			
heet khimawa	nt@em	nkavalo	bal co	m

heet.khimawat@emkayglobal.com +91 22 6612 1275

Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281


Soumya Jain

soumya.jain@emkayglobal.com +91 22 6612 1262

Enkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in charts

Exhibit 1: Credit growth moderated a bit due to deceleration in overseas book, although continues to remain at healthy levels




Source: Company, Emkay Research

Exhibit 3: Credit card spends have moderated a bit in Nov




Source: RBI, Emkay Research

Exhibit 5: Slippages were higher, mainly from KCC card portfolio...




Source: Company, Emkay Research

Exhibit 7: Return ratios remain strong, led by healthy core profitability and lower LLP




Source: Company, Emkay Research (Note - ROA,ROE are annualized)

Exhibit 2: Bank reported the highest-ever margins benefitting from the healthy yield on loans and asset re-pricing




Source: Company, Emkay Research

Exhibit 4: Corporate watch-list (<BB portfolio) further declined to Rs55.8bn/0.6% of loans due to upgrades and slippages into NPA




Source: Company, Emkay Research

Exhibit 6: ...but healthy recoveries and upgrades led to a 12bps reduction in GNPA to 3.1%



Source: Company, Emkay Research

Exhibit 8: RoE to improve to a decadal high of ~18%, led by strong core profitability and lower provisions




E are annualized) Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 299 of Singapore.

Exhibit 9: The stock is trading at 2.1x its one-year forward P/ABV, adjusted for the subsidiary's valuation, and still has scope for a re-rating



Source: Bloomberg, Emkay Research

Exhibit 10: ICICI Bank's SOTP valuation

ICICI Bank – SOTP valuation	Stake (%)	Value per share (Rs)	Basis of valuation
ICICI Standalone (A)		1031	2.9x Dec'24E ABV (adj for investments)
Non-Banking Subsidiaries			
ICICI Prudential Life Insurance	53%	66	2.1x Dec 24E EV
ICICI Lombard General Insurance	48%	74	35x Dec 24E PAT
ICICI Asset Management Company	51%	42	7% of Dec 24E AUM
ICICI Securities	75%	69	25x Dec 24E PE
Other Subsidiaries	100%	25	
Value of Non-Banking Business		276	
Value Post Holding Co. discount (209	%) (B)	220	
Value of the bank (A+B)		1250	
Current market price		870	
Upside (%)		44%	
Contribution of subs to TP (%)		18%	
Source: Emkay Research			

Exhibit 11: Actual vs Estimates (Q3FY23)

Rs mn	Actuals	Estin	nates	% Vari	ation	Commonto
		Emkay	Consensus	Emkay	Consensus	Comments
Net income	2,14,886	2,10,631	2,09,650	2%	2%	Better margins, partly offset by lower other income, led to beat
PPOP	1,32,712	1,25,732	1,26,289	6%	5%	Higher net income and contained opex led to beat
PAT	83,119	80,799	82,421	3% 1%		Higher PPOP, partly offset by higher LLP, led to beat

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 12: Quarterly Summary

Rs (mn)	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	YoY (%)	QoQ (%)	FY22	FY23E	YoY (%)
Interest Earned	220,826	226,749	236,715	260,330	285,056	29	9	863,745	1,084,105	26
Interest Exp	98,466	100,703	104,615	112,462	120,407	22	7	389,085	476,897	23
Net Interest Income	122,360	126,046	132,100	147,868	164,650	35	11	474,661	607,208	28
Global NIMs (reported)	3.96	4.00	4.01	4.31	4.65	69bps	34bps	3.84	4.32	47bps
Non-interest Income	49,871	47,374	46,652	50,549	50,236	1	-1	185,175	203,490	10
Operating Expenses	70,749	70,490	75,663	81,614	82,174	16	1	267,333	328,014	23
Pre Provisioning Profit	101,483	102,929	103,089	116,803	132,712	31	14	392,503	482,684	23
Provision & Contingencies	20,073	10,690	11,438	16,445	22,574	12	37	86,414	61,024	-29
РВТ	81,410	92,240	91,651	100,358	110,138	35	10	306,089	421,660	38
Income Tax Expense (Gain)	19,471	22,053	22,601	24,780	27,019	39	9	72,694	106,258	46
Net Profit/(Loss)	61,938	70,187	69,049	75,578	83,119	34	10	233,395	315,402	35
Gross NPA (%)	4.13	3.60	3.41	3.19	3.07	-106bps	-12bps	3.76	2.89	-87bps
Net NPA (%)	0.85	0.76	0.70	0.61	0.55	-30bps	-6bps	0.81	0.74	-7bps
Deposits (Rs in bn)	10,175	10,646	10,503	10,900	11,220	10	4	10,646	11,729	10
Net Advances (Rs in bn)	8,140	8,590	8,956	9,386	9,740	20	5	8,590	10,221	19
Source: Company, Emkay Research										

Exhibit 13: Revision in estimates

Y/E March (Rs mn)	FY23E			FY24E			FY25E			
	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change	
Net income	807,865	810,698	0.35%	967,203	935,878	-3.24%	1,152,301	1,103,449	-4.24%	
PPOP	470,685	482,684	2.5%	567,808	556,129	-2.1%	679,185	665,645	-2.0%	
PAT	303,405	315,402	4.0%	365,579	372,097	1.8%	432,744	435,408	0.6%	
EPS (Rs)	43.6	45.3	3.8%	52.5	53.3	1.5%	62.2	62.4	0.3%	
BV (Rs)	277.1	278.0	0.3%	321.6	323.3	0.5%	374.8	376.7	0.5%	

Source: Company, Emkay Research

Exhibit	14:	Key	assumptions
---------	-----	-----	-------------

	FY22A	FY23E	FY24E	FY25E
Loan Growth %	17.1	19.0	20.6	20.7
Deposit Growth %	14.2	10.2	18.1	19.7
NIM %	3.8	4.3	4.3	4.2
GNPA %	3.8	2.9	2.3	2.0
Credit Cost %	0.7	0.6	0.5	0.6
Yield on Advances	8.1	8.9	9.3	9.6
Cost of Deposits	3.3	3.6	4.3	4.7

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

India Equity	Research	Result	Update

Exhibit 15: Key ratios and trends

Exhibit 15: Key ratios and trends	3QFY21	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23
Loans (Rs mn)	6,990,175	7,337,291	7,385,979	7,649,374	8,139,916	8,590,204	8,956,248	9,385,628	9,740,475
growth (YoY)	10.0	13.7	17.0	17.2	16.4	17.1	21.3	22.7	19.7
Composition %									
- Corporate - Domestic	24	24	24	23	24	23	23	23	23
- Overseas	6	5	5	5	5	5	5	4	4
- SME	4	4	4	4	4	5	4	4	5
- Retail + Rural + BB	66	67	67	68	68	68	68	69	70
- Retail	51	52	52	52	53	53	53	54	54
- Rural	10	10	10	9	9	9	9	9	9
- Business Banking	5	5	5	6	6	6	6	7	7
Deposit (Rs mn)	8,743,476	9,325,222	9,262,239	9,774,486	10,174,667	10,645,716	10,503,490	10,900,080	11,220,495
growth (YoY)	22.1	21.0	15.5	17.4	16.4	14.2	13.4	11.5	10.3
CASA (%)	45.2	46.3	45.9	46.1	47.2	48.7	46.9	46.6	45.3
CA (%)	13.4	14.6	12.8	13.5	14.4	14.9	13.4	13.3	13.0
SA (%)	31.9	31.7	33.1	32.6	32.9	33.8	33.5	33.3	32.4
Asset Quality/Capital									
GNPA %	4.4	5.0	5.2	4.8	4.1	3.6	3.4	3.2	3.1
NNPA %	0.6	1.1	1.2	1.0	0.9	0.8	0.7	0.6	0.6
PCR %	86.1	77.8	78.4	80.3	80.2	79.5	79.9	81.3	82.6
Slippages (Rs mn)	4,710	118,180	72,310	55,780	40,180	42,040	58,250	43,660	57,230
Slippages %	0.3	7.3	4.6	3.4	2.3	2.3	3.2	2.3	2.8
Restructured loans (% of loans)	0.5	0.5	0.7	1.3	1.2	1.0	0.8	0.7	0.5
CAR %	18.0	19.1	18.7	18.3	19.4	19.2	18.0	16.9	16.3
Tier I %	16.7	18.1	17.7	17.3	18.4	18.4	17.3	16.2	15.5
DOE Decomposition %									
ROE Decomposition %	2.4	2.4	2.0	0.7	0.7	2.0	0.7		
NII	3.4	3.4	3.6	3.7	3.7	3.6	3.7	4.1	4.4
Other Income (Ex Treasury)	1.3	1.4	1.2	1.4	1.5	1.3	1.3	1.4	1.3
Treasury	0.3	(0.0)	0.1	0.1	0.0	0.0	0.0	(0.0)	0.0
Opex	2.0	2.0	2.0	2.1	2.2	2.0	2.1	2.2	2.2
PPOP	3.0	2.8	2.9	3.2	3.1	3.0	2.9	3.2	3.5
Provisions	0.9	1.0	0.9	0.9	0.6	0.3	0.3	0.5	0.6
PBT	2.1	1.9	2.0	2.3	2.5	2.7	2.6	2.8	2.9
Тах	0.4	0.4	0.5	0.5	0.6	0.6	0.6	0.7	0.7
ROA	1.7	1.5	1.5	1.8	1.9	2.0	2.0	2.1	2.2
ROE	14.1	12.1	12.3	14.3	15.5	16.8	15.9	16.8	17.8

Source: Company, Emkay Research

Key Financials (Standalone)

Income Statement

FY21	FY22	FY23E	FY24E	FY25E
389,893	474,661	607,208	697,720	814,591
189,685	185,175	203,490	238,158	288,858
104,868	126,397	149,148	180,469	220,172
579,578	659,836	810,698	935,878	1,103,449
215,608	267,333	328,014	379,749	437,804
363,970	392,503	482,684	556,129	665,645
312,232	385,477	479,972	552,061	658,323
162,144	86,414	61,024	58,673	83,549
201,826	306,089	421,660	497,456	582,097
39,900	72,694	106,258	125,359	146,688
20	24	25	25	25
161,926	233,395	315,402	372,097	435,408
	389,893 189,685 104,868 579,578 215,608 363,970 312,232 162,144 201,826 39,900 20	389,893 474,661 189,685 185,175 104,868 126,397 579,578 659,836 215,608 267,333 363,970 392,503 312,232 385,477 162,144 86,414 201,826 306,089 39,900 72,694 20 24	389,893 474,661 607,208 189,685 185,175 203,490 104,868 126,397 149,148 579,578 659,836 810,698 215,608 267,333 328,014 363,970 392,503 482,684 312,232 385,477 479,972 162,144 86,414 61,024 201,826 306,089 421,660 39,900 72,694 106,258 20 24 25 <td>389,893 474,661 607,208 697,720 189,685 185,175 203,490 238,158 104,868 126,397 149,148 180,469 579,578 659,836 810,698 935,878 215,608 267,333 328,014 379,749 363,970 392,503 482,684 556,129 312,232 385,477 479,972 552,061 162,144 86,414 61,024 58,673 201,826 306,089 421,660 497,456 39,900 72,694 106,258 125,359 20 24 25 25</td>	389,893 474,661 607,208 697,720 189,685 185,175 203,490 238,158 104,868 126,397 149,148 180,469 579,578 659,836 810,698 935,878 215,608 267,333 328,014 379,749 363,970 392,503 482,684 556,129 312,232 385,477 479,972 552,061 162,144 86,414 61,024 58,673 201,826 306,089 421,660 497,456 39,900 72,694 106,258 125,359 20 24 25 25

Balance Sheet

Y/E – March (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity	13,834	13,900	13,956	13,956	13,956
Reserves	1,461,258	1,691,220	1,957,136	2,272,782	2,644,774
Net worth	1,475,092	1,705,120	1,971,092	2,286,738	2,658,730
Deposits	9,325,222	10,645,716	11,729,498	13,858,273	16,590,717
Borrowings	743,851	933,807	1,167,258	1,400,710	1,680,852
Total liabilities	12,304,327	14,112,977	15,751,127	18,862,291	22,372,097
Cash and bank	460,312	601,208	673,353	754,156	844,654
Investments	2,812,865	3,102,410	3,434,253	4,059,752	4,828,915
Loans	7,337,291	8,590,204	10,221,330	12,325,106	14,870,389
Others	734,112	648,401	757,429	900,465	1,072,320
Total assets	12,304,327	14,112,977	15,751,127	18,862,291	22,372,097

Key Ratios (%)

Y/E – March	FY21	FY22	FY23E	FY24E	FY25E
NIM	3.6	3.8	4.3	4.3	4.2
Non-II/avg. assets	1.6	1.4	1.4	1.4	1.4
Fee income/avg. assets	0.9	1.0	1.0	1.0	1.1
Opex/avg assets	1.9	2.0	2.2	2.2	2.1
Provisions/avg assets	1.4	0.7	0.4	0.3	0.4
PBT/avg assets	1.7	2.3	2.8	2.9	2.8
Tax/avg assets	0.3	0.6	0.7	0.7	0.7
RoA	1.4	1.8	2.1	2.2	2.1
RoAE	12.6	15.0	17.5	17.7	17.8
GNPA (%)	5.3	3.8	2.9	2.3	2.0
NNPA (%)	1.2	0.8	0.7	0.6	0.6
Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	24.2	33.7	45.3	53.3	62.4
BVPS	215.7	241.3	278.5	323.3	376.7
ABVPS	206.7	234.7	271.4	315.9	368.1
DPS	0.0	5.0	7.0	8.0	9.0
Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	26.9	19.3	14.4	12.2	10.4
P/BV	3.1	2.7	2.3	2.0	1.7
P/ABV	3.4	2.9	2.5	2.0	1.8
P/PPOP	16.5	15.4	12.6	10.9	9.1
		10.1	12.5	10.0	5.1

Source: Company, Emkay Research This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
NII	17.2	21.7	27.9	14.9	16.8
PPOP	29.5	7.8	23.0	15.2	19.7
PAT	104.2	44.1	35.1	18.0	17.0
Loans	13.7	17.1	19.0	20.6	20.7
Quarterly (Rs mn)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
NII	122,360	126,046	132,100	147,868	164,650
NIM (%)	4.0	4.0	4.0	4.3	4.7
PPOP	101,483	102,929	103,089	116,803	132,712
PAT	61,938	70,187	69,049	75,578	83,119
EPS (Rs)	8.92	10.10	9.92	10.85	11.91
Source: Company, Emkay Research					
Shareholding Pattern (%)	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22
Promoters	-	-	-	-	-
FIIs	56.8	55.1	53.5	54.7	56.0
DIIs	35.0	36.1	37.8	37.2	36.1
Public and Others	8.2	8.8	8.7	8.1	7.9

Source: Capitaline

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
4-Dec-22	931	1,225	12m	Buy	Anand Dama
24-Oct-22	926	1,170	12m	Buy	Anand Dama
24-Jul-22	800	1,025	12m	Buy	Anand Dama
24-Apr-22	748	1,025	12m	Buy	Anand Dama
23-Jan-22	805	1,025	12m	Buy	Anand Dama
4-Dec-21	716	950	12m	Buy	Anand Dama
24-Oct-21	759	950	12m	Buy	Anand Dama
25-Aug-21	691	825	12m	Buy	Anand Dama
25-Jul-21	677	825	12m	Buy	Anand Dama
25-Apr-21	570	730	12m	Buy	Anand Dama
31-Jan-21	537	700	12m	Buy	Anand Dama
20-Jan-21	551	700	12m	Buy	Anand Dama
6-Dec-20	502	600	12m	Buy	Anand Dama
1-Nov-20	393	520	12m	Buy	Anand Dama
26-Jul-20	382	465	12m	Buy	Anand Dama
10-May-20	338	430	12m	Buy	Anand Dama
11-Apr-20	343	600	12m	Buy	Anand Dama
17-Mar-20	367	600	12m	Buy	Anand Dama
27-Jan-20	537	650	12m	Buy	Anand Dama

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 22 Jan 2023 15:49:18 (SGT) Dissemination Date: 22 Jan 2023 15:50:18 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of January 22, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of January 22, 2023.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 22, 2023
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the January 22, 2023

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

RESTRICTIONS ON D	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 01/23/2023 01:59 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.